Select to view the solutions available in your location.
Track orders, get results, manage personal information, and more.
Order tests, track orders, get results, and more.
Learn more about our innovative products and services that help detect cancer earlier and power smarter treatment decisions.
Exact Sciences plans to introduce the Cologuard Plus™ test in 2025, building on a decade of patient impact.
Find out how our scientific rigor, quality standards, and development of future tests make us a leader in cancer testing and treatment guidance.
How one revolutionary test could change the health of millions.
Learn all about Exact Sciences, including our purpose, the people who drive it, our history, and the impact we’ve made.
Several Exact Sciences initiatives address disparities in cancer outcomes among U.S. Latinos.
Explore stories, news, and events that highlight our innovation, technology, and people fighting cancer on all fronts.
Today marks a turning point in the fight to eradicate colorectal cancer. Pfizer and Exact Sciences launched a partnership to get more people screened for this preventable disease by expanding the Cologuard sales force to educate health care providers, increase our health system integration and efficiently grow our Cologuard marketing campaigns.
This partnership can make an extraordinary impact on more people like Sue Pickering. At age 62, Sue had never been screened for colorectal cancer but completed a Cologuard test at the encouragement of her friend and physician. Sue’s results came back positive and after a colonoscopy, she was diagnosed with Stage II colorectal cancer. After surgery and a few rounds of preventive chemotherapy, Sue has no evidence of disease.
Sue’s Cologuard result didn’t just impact her. She is the fulltime caregiver for her adult daughter, who has a disability. When we recently asked about her Cologuard result, Sue pointed out, “My first thought was not about me, but what would happen to my daughter. If this hadn’t been caught early, I don’t know what would have happened to her.”
Getting more patients screened so their colorectal cancer can be detected early will be critical to achieving the Exact Sciences mission of eradicating this disease. Colorectal cancer is recognized as the most preventable yet least prevented form of cancer and remains the second leading cause of cancer death in the U.S., with more than 50,000 deaths each year. Nine out of 10 people survive more than five years when colorectal cancer is diagnosed in Stage I or II, but only one out of 10 people survive more than five years when the disease is diagnosed in Stage IV. While patient outcomes can be improved through early detection, fewer than two-thirds of people are up-to-date with recommended colorectal cancer screening guidelines.
Through this partnership, Exact Sciences can impact the lives of more people like Sue by combining the power of Cologuard and our talented team, with Pfizer’s experience, relationships and resources. The agreement, which continues through 2021, is built around three areas:
Exact Sciences is committed to combining our strong team with some of the industry’s best patient advocates. This began nine years ago when we partnered with Mayo Clinic to develop Cologuard and continues today through our partnership with Pfizer. Together, we are poised to change the lives of so many more people.
More details about this agreement are available in our press release here and in a form 8-K here that Exact Sciences filed in compliance with Securities and Exchange Commission rules.